Julie Errington

805 total citations
25 papers, 573 citations indexed

About

Julie Errington is a scholar working on Molecular Biology, Neurology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Julie Errington has authored 25 papers receiving a total of 573 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 10 papers in Neurology and 10 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Julie Errington's work include Neuroblastoma Research and Treatments (10 papers), Cancer therapeutics and mechanisms (9 papers) and Childhood Cancer Survivors' Quality of Life (5 papers). Julie Errington is often cited by papers focused on Neuroblastoma Research and Treatments (10 papers), Cancer therapeutics and mechanisms (9 papers) and Childhood Cancer Survivors' Quality of Life (5 papers). Julie Errington collaborates with scholars based in United Kingdom, Australia and India. Julie Errington's co-authors include Gareth J. Veal, Alan V. Boddy, Andrew D.J. Pearson, Michael Cole, David R. Newell, Nicola J. Curtin, Xiaohong Lü, John Lunec, Christopher Hill and A.B.M. Foot and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Julie Errington

24 papers receiving 564 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julie Errington United Kingdom 16 303 158 109 103 85 25 573
Takuro Nishikawa Japan 11 221 0.7× 240 1.5× 53 0.5× 35 0.3× 64 0.8× 60 677
S. Murray Yule United Kingdom 16 266 0.9× 233 1.5× 133 1.2× 54 0.5× 178 2.1× 21 784
Z. Günnur Dikmen Türkiye 17 562 1.9× 118 0.7× 42 0.4× 25 0.2× 46 0.5× 40 974
Joanna Regis United States 10 270 0.9× 550 3.5× 160 1.5× 20 0.2× 35 0.4× 14 660
Joseph A. Sinkule United States 12 242 0.8× 276 1.7× 51 0.5× 32 0.3× 49 0.6× 14 489
Qun Hu China 11 278 0.9× 137 0.9× 33 0.3× 27 0.3× 25 0.3× 78 628
Seiji Doi Japan 12 365 1.2× 511 3.2× 78 0.7× 37 0.4× 17 0.2× 20 737
Shuangnian Xu China 17 354 1.2× 131 0.8× 29 0.3× 25 0.2× 44 0.5× 47 749
Yuan‐Chin Tsai United States 7 458 1.5× 351 2.2× 36 0.3× 18 0.2× 40 0.5× 12 833
M Slavík United States 12 191 0.6× 127 0.8× 38 0.3× 20 0.2× 89 1.0× 32 592

Countries citing papers authored by Julie Errington

Since Specialization
Citations

This map shows the geographic impact of Julie Errington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Errington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Errington more than expected).

Fields of papers citing papers by Julie Errington

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Errington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Errington. The network helps show where Julie Errington may publish in the future.

Co-authorship network of co-authors of Julie Errington

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Errington. A scholar is included among the top collaborators of Julie Errington based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Errington. Julie Errington is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Berry, Philip, Julie Errington, Philip D. Jeffrey, et al.. (2021). Development of a Lc–Ms/Ms Method for the Quantification of Toxic Payload Dm1 Cleaved from Bt1718 in a Phase I Study. Bioanalysis. 13(2). 101–113. 26 indexed citations
2.
Barnett, S., Julie Errington, Julieann Sludden, et al.. (2021). Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population. Pharmaceuticals. 14(3). 272–272. 19 indexed citations
3.
Berry, Philip, Julie Errington, Jizhong Liu, et al.. (2019). Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia—a report from the UKALL 2011 trial. European Journal of Cancer. 120. 75–85. 21 indexed citations
4.
Duong, Janna K., Gareth J. Veal, Christa E. Nath, et al.. (2018). Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re‐evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. British Journal of Clinical Pharmacology. 85(1). 136–146. 8 indexed citations
5.
Veal, Gareth J., Julie Errington, Julia Chisholm, et al.. (2016). Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens. Cancer Chemotherapy and Pharmacology. 77(4). 685–692. 15 indexed citations
6.
Errington, Julie, et al.. (2016). Investigating the Experiences of Childhood Cancer Patients and Parents Participating in Optional Nontherapeutic Clinical Research Studies in the UK. Pediatric Blood & Cancer. 63(7). 1193–1197. 4 indexed citations
7.
Veal, Gareth J., Michael Cole, Girish Chinnaswamy, et al.. (2016). Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma. European Journal of Cancer. 55. 56–64. 50 indexed citations
8.
Veal, Gareth J., Julie Errington, James Hayden, et al.. (2015). Carboplatin therapeutic monitoring in preterm and full-term neonates. European Journal of Cancer. 51(14). 2022–2030. 30 indexed citations
9.
10.
Veal, Gareth J., Julie Errington, Sophie E. Rowbotham, et al.. (2012). Adaptive Dosing Approaches to the Individualization of 13- Cis -Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma. Clinical Cancer Research. 19(2). 469–479. 38 indexed citations
11.
Chinnaswamy, Girish, Julie Errington, A.B.M. Foot, et al.. (2011). Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy. European Journal of Cancer. 47(10). 1556–1563. 20 indexed citations
12.
Veal, Gareth J., Michael Cole, Julie Errington, et al.. (2009). Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. Cancer Chemotherapy and Pharmacology. 65(6). 1057–1066. 15 indexed citations
13.
Picton, Susan, et al.. (2008). Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma. Cancer Chemotherapy and Pharmacology. 63(4). 749–752. 14 indexed citations
14.
Veal, Gareth J., Michael Cole, Julie Errington, et al.. (2007). Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma – a study of the United Kingdom Children's Cancer Study Group. British Journal of Cancer. 96(3). 424–431. 42 indexed citations
15.
Veal, Gareth J., Julie Errington, Michael J. Tilby, et al.. (2007). Adaptive dosing and platinum–DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. British Journal of Cancer. 96(5). 725–731. 32 indexed citations
16.
Veal, Gareth J., Julie Errington, Huw D. Thomas, Alan V. Boddy, & Stephen P. Lowis. (2006). Biliary excretion of etoposide in children with cancer. Cancer Chemotherapy and Pharmacology. 58(3). 415–417. 6 indexed citations
17.
Veal, Gareth J., Julie Errington, Caroline Ellershaw, Andrew Pearson, & Alan V. Boddy. (2005). A study to investigate the pharmacokinetics of carboplatin and etoposide in infants with neuroblastoma. Cancer Research. 65. 693–693. 2 indexed citations
18.
Veal, Gareth J., Julie Errington, Julieann Sludden, et al.. (2003). Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography–mass spectrometry. Journal of Chromatography B. 795(2). 237–243. 19 indexed citations
19.
Veal, Gareth J., Julie Errington, Christopher P.F. Redfern, Andrew D.J. Pearson, & Alan V. Boddy. (2002). Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells. Biochemical Pharmacology. 63(2). 207–215. 28 indexed citations
20.
Lü, Xiaohong, Julie Errington, Nicola J. Curtin, John Lunec, & David R. Newell. (2001). The impact of p53 status on cellular sensitivity to antifolate drugs.. PubMed. 7(7). 2114–23. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takuro Nishikawa Breakdown of academic impact, for papers by S. Murray Yule Breakdown of academic impact, for papers by Z. Günnur Dikmen Breakdown of academic impact, for papers by Joanna Regis Breakdown of academic impact, for papers by Joseph A. Sinkule Breakdown of academic impact, for papers by Qun Hu Breakdown of academic impact, for papers by Seiji Doi Breakdown of academic impact, for papers by Shuangnian Xu Breakdown of academic impact, for papers by Yuan‐Chin Tsai Breakdown of academic impact, for papers by M Slavík
Rankless by CCL
2026